Issues of efficiency and safety of immunomodulating therapy in the treatment of the chlamydial and herpetic infection of the urogenital tract

Target: to give the clinical and immunologic evaluation of the combined chlamydial and herpetic infection of the urogenital tract and to study the possibility of the immunomodulating therapy at this category of patients. Маterial and methods The open short term prospective randomized clinical and immunologic study comprises 93 women of reproductive age, suffering from chlamydial and herpetic infection of the low section of the reproductive tract. Besides the basic therapy (acyclovir 200 mg 5 times a day No7, azithromycin 1,0 No 1) the index group (n=52) received such immunomodulator as tiloron, the basic therapy group (n=4) received only basic therapy. The experimental group (n=50) comprised apparently healthy women, selected during prophylactic examinations. Results. After the monthly treatment in the experimental group Chlamydia was revealed at 12,1%, HSV at 9,7% of women. In the index group it was 1,9 and 3,8% accordingly. At the repeated control after a month in the index group Chlamydia was not revealed at у 98%, HSV - at 96,1%. It was 87,8 and 80,5% in the experimental group accordingly (р<0,05). Opinions. Demonstration of the high clinical, immunologic and ethologic efficiency of the comprehensive therapy with use of tiloron.

Chlamydia, herpetic infection, tiloron, mucosal immunity